Drug treatment of hypercholesterolaemia

Annals of the Academy of Medicine Singapore

Volumn 27, Issue 6, 1998, Pages 794-799

  Tay, J C ^a   Chee, Y C ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NONE

Author keywords

Cholesterol targets; Coronary heart disease; Lipid lowering drugs; Vascular risks

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; COLESTYRAMINE; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DRUG EFFECT; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; OUTPATIENT; PRACTICE GUIDELINE; RISK FACTOR;

EID: 0032453714     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
2. Shepherd J, Cobbe S M, Ford I, Isles C G, Lorimer A R, MacFarlane P W, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-7.
3. Sacks F M, Pfeffer M A, Moye L A, Rouleau J L, Rutherford J D, Cole T G, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269:3015-22.
5. Betteridge D J, Dodson P M, Durrington P N, Hughes E A, Laker M F, Nicholls D P, et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993; 69:359-69.
6. Pyorala K, Backer G D, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15:1300-31.
7. Schrott H G, Bittner V, Vittinghoff E, Herrington D M, Hulley S. Adherence to National Cholesterol Education Program Treatment Goals in Postmenopausal Women with Heart Disease. JAMA 1997; 227:1281-6.
8. Cohen M V, Byrne M J, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991; 83:1294-304.
9. Hoerger TJ, Bala M V, Bray J W, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998; 82:61-5.
10. Danias P G, O'Mahony S, Radford M J, Korman L, Silvermn D I. Serum cholesterol levels are underevaluated and undertreated. Am J Cardiol 1998; 81:1353-6.
11. Marcelino J J, Feingold K R. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100:605-10.
12. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100:197-204.
13. Kellick K A, Burns K, McAndrew E, Haberl E, Hook N, Ellis A. Outcome monitoring of fluvastatin in a department of veterans affairs lipid clinic. Am J Cardiol 1995; 76:62A-4A
14. Nawrocki J W, Weiss S R, Davidson M H, Sprecher D L, Schwartz S L, Lupien P J, et al. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15:678-82.
15. Cashin-Hemphill L, Mack W J, Pogoda J M, Sanmarco M E, Azen S P, Blankenhorn D H. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 1990; 264:3013-7.
16. Schrott H G, Stein E A, Dujovne C A, Davidson M H, Goris G B, Oliphant T H, et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low dose colestipol plus lovastatin combination therapy. Am J Cardiol 1994; 75:34-9.
17. Pasternak R C, Brown L E, Stone P H, Silverman D I, Gibson C M, Sacks F M. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. Ann Intern Med 1996; 125:529-40.
18. Hunninghake D B, Stein E A, Dujovne C A, Harris W S, Feldman E B, Miller V T, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993; 328:1214-9.
19. Harris D E, Record N B, Gipson G W, Pearson T A. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol 1998; 81:929-33.